⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8841964 | 0.57 | — | — | |
| SCHEMBL3555065 | 0.54 | — | — | |
| SCHEMBL5318324 | 0.54 | — | — | |
| SCHEMBL19341 | 0.49 | — | — | |
| SCHEMBL3707 | 0.47 | — | — | |
| SCHEMBL17491071 | 0.46 | — | — | |
| SCHEMBL605705 | 0.43 | — | — | |
| SCHEMBL16861374 | 0.43 | — | — | |
| SCHEMBL561897 | 0.41 | — | — | |
| SCHEMBL129122 | 0.41 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118176181-A | SARM1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-110742893-B | Methods of treating cancer with A2A receptor antagonists | 百济神州(北京)生物科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117813306-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-112236423-B | Piperidinyl-3- (aryloxy) propanamides and propionic acid esters | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| CN-117460732-A | Pyrrolopyridone compounds, preparation method and application thereof | 杭州中美华东制药有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117355506-A | RIP1 modulators comprising azetidine cyclic ureas, preparation and use thereof | 维泰瑞隆有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-110087730-B | Treatment of cancer using a combination comprising a PARP inhibitor | 百济神州(苏州)生物科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-109475536-B | Combination of a PD-l antagonist and a RAF inhibitor for the treatment of cancer | 百济神州有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-112313234-B | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-113773315-A | Highly selective deuterated inhibitors of cyclin dependent kinase 2(CDK2) | 无锡佰翱得生物科学有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-112313234-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-106687446-B | 5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible kinase inhibitors of T790M/WT-EGFR and uses thereof | 百济神州(北京)生物科技有限公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-110872289-A | Novel 8-substituted imidazo [1,5-a ] pyridines as IDO1 and/or TDO inhibitors | 百济神州(北京)生物科技有限公司 | 2020-03-10 | — | — | CN | disclosed |
| EP-2714688-B1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-5597776-A | ANTAGONIST FOR HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-28 | — | — | US | disclosed |
| EP-0537463-A2 | Substituted pyrido(2,3-d)pyrimidines as antidotes | BASF Aktiengesellschaft (DE) | 1993-04-21 | — | — | EP | disclosed |